Comparative Pharmacology
Head-to-head clinical analysis: PANMYCIN versus RETET.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PANMYCIN versus RETET.
PANMYCIN vs RETET
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Tetracycline antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-tRNA from attaching to the A site.
RETET is a selective estrogen receptor modulator (SERM) that competitively inhibits estrogen binding to estrogen receptors, thereby blocking estrogen-mediated signaling in target tissues.
250-500 mg PO q6h or 500 mg to 1 g IV q6h; maximum 4 g/day
No standard dosing available; RETET is not a recognized therapeutic agent. Please verify drug name.
None Documented
None Documented
Terminal elimination half-life is 6-8 hours in patients with normal renal function. Half-life is significantly prolonged (up to 80 hours) in anuria, requiring dose adjustment.
Terminal elimination half-life 18-24 hours in healthy adults; prolonged to 30-40 hours in moderate renal impairment (CrCl 30-50 mL/min).
Primarily renal excretion of unchanged drug via glomerular filtration; 80-90% recovered in urine within 24 hours. Biliary/fecal excretion accounts for <5%.
Renal: 70-80% unchanged; Fecal: 10-15%; Biliary: <5%.
Category C
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic